IMC-A12 (cixutumumab)
Sponsors
Eli Lilly and Company
Conditions
Adenocarcinoma of the ProstateAdipocytic SarcomaColon CancerEwing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET)Head and Neck CancerLeiomyosarcomaMetastatic Breast CancerNon-Small Cell Lung Cancer
Phase 2
Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
CompletedNCT00520481
Start: 2007-08-31End: 2013-08-31Updated: 2018-07-19
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
CompletedNCT00617734
Start: 2008-03-31End: 2012-07-31Updated: 2018-04-17
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
CompletedNCT00668148
Start: 2008-07-31End: 2012-02-29Updated: 2018-07-17
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
CompletedNCT00728949
Start: 2008-08-31End: 2015-02-28Updated: 2018-06-06
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
TerminatedNCT00845039
Start: 2009-05-31End: 2011-02-28Updated: 2018-07-02
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
CompletedNCT00870870
Start: 2009-03-31End: 2012-05-31Updated: 2018-06-01